Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
peripheral T-cell lymphoma (PTCL)
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0199-000
NOC Date:
Details
Strength:
50 mg / vial
Tumour Type:
Lymphoma
Indications:
Peripheral T-cell Lymphoma (PTCL)
Funding Request:
For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse
Funding Request:
For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).
pERC Meeting:
Final Recommendation Issued: